Khiron Life Sciences Corp
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and s… Read more
Khiron Life Sciences Corp (KHRNF) - Total Assets
Latest total assets as of September 2022: $38.45 Million USD
Based on the latest financial reports, Khiron Life Sciences Corp (KHRNF) holds total assets worth $38.45 Million USD as of September 2022.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Khiron Life Sciences Corp - Total Assets Trend (2011–2021)
This chart illustrates how Khiron Life Sciences Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Khiron Life Sciences Corp - Asset Composition Analysis
Current Asset Composition (December 2021)
Khiron Life Sciences Corp's total assets of $38.45 Million consist of 56.2% current assets and 43.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.1% |
| Accounts Receivable | $2.88 Million | 6.8% |
| Inventory | $9.45 Million | 22.4% |
| Property, Plant & Equipment | $13.56 Million | 32.1% |
| Intangible Assets | $868.00K | 2.1% |
| Goodwill | $4.08 Million | 9.6% |
Asset Composition Trend (2011–2021)
This chart illustrates how Khiron Life Sciences Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Khiron Life Sciences Corp's current assets represent 56.2% of total assets in 2021, a decrease from 100.0% in 2011.
- Cash Position: Cash and equivalents constituted 21.1% of total assets in 2021, down from 100.0% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 0.0% in 2011.
- Asset Diversification: The largest asset category is property, plant & equipment at 32.1% of total assets.
Khiron Life Sciences Corp Competitors by Total Assets
Key competitors of Khiron Life Sciences Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Khiron Life Sciences Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Khiron Life Sciences Corp generates 0.30x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Khiron Life Sciences Corp is currently not profitable relative to its asset base.
Khiron Life Sciences Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.91 | 4.94 | 2.15 |
| Quick Ratio | 0.89 | 3.42 | 2.15 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.72 Million | $ 25.68 Million | $ 72.07K |
Khiron Life Sciences Corp - Advanced Valuation Insights
This section examines the relationship between Khiron Life Sciences Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -42.2% |
| Total Assets | $42.27 Million |
| Market Capitalization | $20.49K USD |
Valuation Analysis
Below Book Valuation: The market values Khiron Life Sciences Corp's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Khiron Life Sciences Corp's assets decreased by 42.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Khiron Life Sciences Corp (2011–2021)
The table below shows the annual total assets of Khiron Life Sciences Corp from 2011 to 2021.
| Year | Total Assets | Change |
|---|---|---|
| 2021-12-31 | $42.27 Million | -42.23% |
| 2020-12-31 | $73.18 Million | -10.66% |
| 2019-12-31 | $81.91 Million | +103.01% |
| 2018-12-31 | $40.35 Million | +27251.79% |
| 2017-12-31 | $147.52K | +1459.39% |
| 2016-12-31 | $9.46K | +39.88% |
| 2015-12-31 | $6.76K | -80.74% |
| 2014-12-31 | $35.11K | -70.26% |
| 2013-12-31 | $118.07K | -44.32% |
| 2012-12-31 | $212.03K | -31.63% |
| 2011-12-31 | $310.14K | -- |